Want to see HK:2348 full AI Analyst Report?
2348 Stock Chart & Stats
HK$1.00
HK$0.02(2.00%)
At close: 4:00 PM EDT
HK$1.00
HK$0.02(2.00%)
Day’s Range― - ―
52-Week RangeHK$0.98 - HK$1.40
Previous CloseN/A
Volume24.00K
Average Volume (3M)355.07K
Market Cap
HK$1.57B
Enterprise ValueHK$258.31M
Total Cash (Recent Filing)HK$1.58B
Total Debt (Recent Filing)HK$77.51M
Price to Earnings (P/E)6.4
Beta0.34
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield6.06%
Share Statistics
EPS (TTM)0.14
Shares Outstanding1,506,391,000
10 Day Avg. Volume239,600
30 Day Avg. Volume355,066
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)0.49
Price to Sales (P/S)1.36
P/FCF Ratio7.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low Leverage / Strong Balance SheetExtremely low debt and sizable equity provide durable financial flexibility: the company can fund working capital, capex or M&A without reliance on external debt, better withstand industry shocks, and support operations and strategic initiatives over the next several quarters to years.
High Margins Across P&LStrong gross and operating margins indicate structural profitability from product mix or manufacturing efficiency. Durable margins give the company room to absorb cost pressures, fund R&D or marketing, and sustain cash generation even if top-line growth moderates.
Improved Operating & Free Cash FlowMaterial improvement in OCF and FCF enhances internal funding capacity and reduces financing needs. Consistent cash generation supports capex, working capital and shareholder returns, and provides a buffer to manage cyclicality or fund strategic investments over the medium term.
Bears Say
Earnings Volatility / Sharp Net Income DropA large year‑over‑year earnings swing undermines predictability of profits and impairs planning for reinvestment or distributions. Persistent earnings volatility can reduce stakeholder confidence and complicate longer‑term investment decisions and resource allocation.
Uneven Revenue TrendsFluctuating sales indicate structural demand or execution inconsistencies. Uneven top‑line makes capacity planning, pricing strategy and market-share gains harder to sustain, increasing the risk that margins and cash flow will re‑reverse if growth does not stabilize.
Variable Cash Conversion HistoricallyInconsistent conversion of earnings to cash creates a recurring liquidity risk: profits may not translate into spendable cash reliably, constraining dividends, capex or debt servicing in weaker years despite accounting profitability.
Dawnrays Pharmaceutical Holdings Ltd. News
2348 FAQ
What was Dawnrays Pharmaceutical Holdings Ltd.’s price range in the past 12 months?
Dawnrays Pharmaceutical Holdings Ltd. lowest stock price was HK$0.98 and its highest was HK$1.40 in the past 12 months.
What is Dawnrays Pharmaceutical Holdings Ltd.’s market cap?
Dawnrays Pharmaceutical Holdings Ltd.’s market cap is HK$1.57B.
When is Dawnrays Pharmaceutical Holdings Ltd.’s upcoming earnings report date?
Dawnrays Pharmaceutical Holdings Ltd.’s upcoming earnings report date is Aug 21, 2026 which is in 14 days.
How were Dawnrays Pharmaceutical Holdings Ltd.’s earnings last quarter?
Dawnrays Pharmaceutical Holdings Ltd. released its earnings results on Mar 27, 2026. The company reported HK$0.08 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.08.
Is Dawnrays Pharmaceutical Holdings Ltd. overvalued?
According to Wall Street analysts Dawnrays Pharmaceutical Holdings Ltd.’s price is currently Overvalued.
Does Dawnrays Pharmaceutical Holdings Ltd. pay dividends?
Dawnrays Pharmaceutical Holdings Ltd. pays a Annually dividend of HK$0.048 which represents an annual dividend yield of 6.06%. See more information on Dawnrays Pharmaceutical Holdings Ltd. dividends here
What is Dawnrays Pharmaceutical Holdings Ltd.’s EPS estimate?
Dawnrays Pharmaceutical Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dawnrays Pharmaceutical Holdings Ltd. have?
Dawnrays Pharmaceutical Holdings Ltd. has 1,506,391,000 shares outstanding.
What happened to Dawnrays Pharmaceutical Holdings Ltd.’s price movement after its last earnings report?
Dawnrays Pharmaceutical Holdings Ltd. reported an EPS of HK$0.08 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.791%.
Which hedge fund is a major shareholder of Dawnrays Pharmaceutical Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:2348
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dawnrays Pharmaceutical Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.03%
12-Months-Change
Fundamentals
Return on Equity
6.06%
Trailing 12-Months
Asset Growth
4.66%
Trailing 12-Months
Company Description
Dawnrays Pharmaceutical Holdings Ltd.
Dawnrays Pharmaceutical (Holdings) Limited operates as an investment holding company, primarily engaged in the creation, production, and global distribution of generic pharmaceutical medicines, with a focus on Mainland China and international markets. Its operations are divided into two main divisions: Intermediates and Bulk Medicines, and Finished Drugs. The company's diverse product portfolio features a range of antibiotics, including pharmaceutical intermediates, bulk active ingredients, powdered formulations for injection, and oral antibiotic preparations. Furthermore, Dawnrays offers specialized medications addressing various bodily systems and conditions, such as those for cardiovascular health, allergies, Hepatitis B Virus (HBV), digestive and urinary issues, antipyretic-analgesic (fever and pain relief), respiratory ailments, and endocrine disorders. These system-specific drugs are dispensed in familiar forms like tablets, capsules, and granules. Founded in 1995, the firm maintains its headquarters in Wan Chai, Hong Kong, and is a subsidiary of Fortune United Group Limited.
Technical Analysis
Lee's Pharmaceutical Holdings Limited
―
Fusen Pharmaceutical Co., Ltd.
―
JBM (Healthcare) Ltd.
―
Jacobson Pharma Corporation Limited
―
VISEN Pharmaceuticals
―